{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:32:58Z","timestamp":1770150778393,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-025-02291-y","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:58:50Z","timestamp":1770105530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioresorbable Scaffolds: Ready for a Rematch?"],"prefix":"10.1007","volume":"28","author":[{"given":"Oludamilola","family":"Akinmolayemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swagata","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon W.","family":"Bienstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"1","key":"2291_CR1","first-page":"128","volume":"69","author":"JA Ormiston","year":"2007","unstructured":"Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007;69(1):128\u201331.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"2291_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","volume":"75","author":"MV Madhavan","year":"2020","unstructured":"Madhavan MV, Kirtane AJ, Redfors B, Genereux P, Ben-Yehuda O, Palmerini T, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2020;75(6):590\u2013604.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2291_CR3","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.4244\/EIJ-D-23-00326","volume":"19","author":"M Haude","year":"2023","unstructured":"Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, et al. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study. EuroIntervention. 2023;19(5):e414\u201322.","journal-title":"EuroIntervention"},{"issue":"10","key":"2291_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.4244\/EIJV12I10A209","volume":"12","author":"YJ Zhang","year":"2016","unstructured":"Zhang YJ, Wang XZ, Fu G, Jing QM, Wang G, Jin CY, et al. Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial. EuroIntervention. 2016;12(10):1279\u201387.","journal-title":"EuroIntervention"},{"issue":"Suppl 9","key":"2291_CR5","doi-asserted-by":"publisher","first-page":"S950","DOI":"10.21037\/jtd.2017.07.25","volume":"9","author":"A Mattesini","year":"2017","unstructured":"Mattesini A, Bartolini S, Sorini Dini C, Valente S, Parodi G, Stolcova M, et al. The DESolve novolimus bioresorbable Scaffold: from bench to bedside. J Thorac Dis. 2017;9(Suppl 9):S950\u20138.","journal-title":"J Thorac Dis"},{"issue":"Suppl 1","key":"2291_CR6","first-page":"630","volume":"87","author":"Y Wu","year":"2016","unstructured":"Wu Y, Shen L, Ge L, Wang Q, Qian J, Zhang F, et al. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery. Catheter Cardiovasc Interv. 2016;87(Suppl 1):630\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"20","key":"2291_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905\u201315.","journal-title":"N Engl J Med"},{"issue":"21","key":"2291_CR8","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol. 2015;66(21):2298\u2013309.","journal-title":"J Am Coll Cardiol"},{"issue":"47","key":"2291_CR9","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","volume":"36","author":"T Kimura","year":"2015","unstructured":"Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332\u201342.","journal-title":"Eur Heart J"},{"issue":"10059","key":"2291_CR10","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479\u201391.","journal-title":"Lancet"},{"issue":"23","key":"2291_CR11","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","volume":"70","author":"DJ Kereiakes","year":"2017","unstructured":"Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017;70(23):2852\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"2291_CR12","doi-asserted-by":"crossref","unstructured":"Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, AJ, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med. 2017;376(24):2319\u201328.","DOI":"10.1056\/NEJMoa1614954"},{"issue":"4","key":"2291_CR13","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.4244\/EIJ-D-18-00335","volume":"14","author":"RYG Tijssen","year":"2018","unstructured":"Tijssen RYG, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, et al. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention. 2018;14(4):e426\u201333.","journal-title":"EuroIntervention"},{"issue":"10157","key":"2291_CR14","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","volume":"392","author":"GW Stone","year":"2018","unstructured":"Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530\u201340.","journal-title":"Lancet"},{"issue":"23","key":"2291_CR15","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.119.043467","volume":"140","author":"M Sabate","year":"2019","unstructured":"Sabate M, Alfonso F, Cequier A, Romani S, Bordes P, Serra A, et al. Magnesium-based resorbable scaffold versus permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: the MAGSTEMI randomized clinical trial. Circulation. 2019;140(23):1904\u201316.","journal-title":"Circulation"},{"issue":"2","key":"2291_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/eurheartj\/ehy710","volume":"40","author":"RA Byrne","year":"2019","unstructured":"Byrne RA, Alfonso F, Schneider S, Maeng M, Wiebe J, Kretov E, et al. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. Eur Heart J. 2019;40(2):167\u201376.","journal-title":"Eur Heart J"},{"issue":"11","key":"2291_CR17","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.4244\/EIJ-D-20-00024","volume":"16","author":"Y Onuma","year":"2020","unstructured":"Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, et al. Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial. EuroIntervention. 2020;16(11):e938\u201341.","journal-title":"EuroIntervention"},{"issue":"5","key":"2291_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1253\/circj.CJ-19-1184","volume":"84","author":"K Kozuma","year":"2020","unstructured":"Kozuma K, Tanabe K, Hamazaki Y, Okamura T, Ando J, Ikari Y, et al. Long-term outcomes of Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent - a randomized comparison through 5 years in Japan. Circ J. 2020;84(5):733\u201341.","journal-title":"Circ J"},{"issue":"Suppl 1","key":"2291_CR19","first-page":"648","volume":"95","author":"L Song","year":"2020","unstructured":"Song L, Sun Z, Guan C, Yan H, Yu M, Cui J, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): three-year clinical and imaging outcomes. Catheter Cardiovasc Interv. 2020;95(Suppl 1):648\u201357.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"13","key":"2291_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jcin.2021.04.048","volume":"14","author":"L Song","year":"2021","unstructured":"Song L, Xu B, Chen Y, Zhou Y, Jia S, Zhong Z, et al. Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial. JACC Cardiovasc Interv. 2021;14(13):1450\u201362.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"2291_CR21","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.4244\/EIJ-D-21-00651","volume":"18","author":"L Ortega-Paz","year":"2022","unstructured":"Ortega-Paz L, Brugaletta S, Gomez-Lara J, Alfonso F, Cequier A, Romani S, et al. Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial. EuroIntervention. 2022;18(5):e389\u201396.","journal-title":"EuroIntervention"},{"issue":"16","key":"2291_CR22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.4244\/EIJ-D-21-00419","volume":"17","author":"LSM Kerkmeijer","year":"2022","unstructured":"Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, et al. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. EuroIntervention. 2022;17(16):1340\u20137.","journal-title":"EuroIntervention"},{"issue":"3","key":"2291_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jacc.2023.05.003","volume":"82","author":"GW Stone","year":"2023","unstructured":"Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, et al. 5-year outcomes after bioresorbable coronary scaffolds implanted with improved technique. J Am Coll Cardiol. 2023;82(3):183\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2291_CR24","first-page":"222","volume":"19","author":"RL Gao","year":"2023","unstructured":"Gao RL, Xu B, Sun Z, Guan C, Song L, Gao L, et al. First-in-human evaluation of a novel ultrathin sirolimus-eluting iron bioresorbable scaffold: 3-year outcomes of the IBS-FIM trial. EuroIntervention. 2023;19(3):222\u201331.","journal-title":"EuroIntervention"},{"issue":"1","key":"2291_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2024.08.050","volume":"18","author":"DA Power","year":"2025","unstructured":"Power DA, Camaj A, Kereiakes DJ, Ellis SG, Gao R, Kimura T, et al. Early and late outcomes with the absorb bioresorbable vascular scaffold: final report from the ABSORB clinical trial program. JACC Cardiovasc Interv. 2025;18(1):1\u201311.","journal-title":"JACC Cardiovasc Interv"},{"issue":"22","key":"2291_CR26","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.110.970772","volume":"122","author":"PW Serruys","year":"2010","unstructured":"Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301\u201312.","journal-title":"Circulation"},{"issue":"1","key":"2291_CR27","doi-asserted-by":"publisher","first-page":"e014665","DOI":"10.1161\/CIRCINTERVENTIONS.124.014665","volume":"18","author":"KN Hansen","year":"2025","unstructured":"Hansen KN, Troan J, Maehara A, Noori M, Hougaard M, Ellert-Gregersen J, et al. Optimal predilatation treatment before implantation of a magmaris bioresorbable scaffold in coronary artery stenosis: The OPTIMIS trial. Circ Cardiovasc Interv. 2025;18(1):e014665.","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"2291_CR28","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1253\/circj.CJ-16-0818","volume":"80","author":"Y Sotomi","year":"2016","unstructured":"Sotomi Y, Onuma Y, Dijkstra J, Eggermont J, Liu S, Tenekecioglu E, et al. Impact of implantation technique and plaque morphology on strut embedment and scaffold expansion of polylactide bioresorbable scaffold - insights from ABSORB Japan trial. Circ J. 2016;80(11):2317\u201326.","journal-title":"Circ J"},{"issue":"13","key":"2291_CR29","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.jcin.2015.07.026","volume":"8","author":"Y Ishibashi","year":"2015","unstructured":"Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015;8(13):1715\u201326.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"2291_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008383","volume":"13","author":"SY Lee","year":"2020","unstructured":"Lee SY, Kang DY, Hong SJ, Ahn JM, Ahn CM, Park DW, et al. Optical coherence tomography for coronary bioresorbable vascular scaffold implantation: a randomized controlled trial. Circ Cardiovasc Interv. 2020;13(1):e008383.","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"2291_CR31","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.carrev.2020.03.023","volume":"21","author":"Y Ueki","year":"2020","unstructured":"Ueki Y, Yamaji K, Barbato E, Nef H, Brugaletta S, Alfonso F, et al. Randomized comparison of optical coherence tomography versus angiography to guide bioresorbable vascular scaffold implantation: the OPTICO BVS study. Cardiovasc Revasc Med. 2020;21(10):1244\u201350.","journal-title":"Cardiovasc Revasc Med"},{"issue":"1","key":"2291_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2305637","volume":"390","author":"RL Varcoe","year":"2024","unstructured":"Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390(1):9\u201319.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02291-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02291-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02291-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:58:52Z","timestamp":1770105532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02291-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2291"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02291-y","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Stone has received speaker honoraria from Medtronic, Amgen, Boehringer Ingelheim; has served as a consultant to Robocath, Daiichi Sankyo, Vectorious, Miracor, Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Colibri, Bioventrix, MedHub; and has equity\/options from Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter. Dr. Stone\u2019s employer, Mount Sinai Hospital, receives research grants from Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave and PCORI (via Weill Cornell Medical Center). All other authors have no relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"18"}}